openPR Logo
Press release

Focal Segmental Glomerulosclerosis Market Size, Share, Analysis, Industry Report and Forecast 2021-2027

03-07-2022 11:51 AM CET | Health & Medicine

Press release from: Orion Market Research

The global focal segmental glomerulosclerosis (FSGS) market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factors that are expected to boost the market include the increasing prevalence of FSGS, rising focus towards rare diseases, and increasing R&D activity. Moreover, in both developed and emerging markets, increasing demand for the kidney transplants and a higher rate of hospitalizations have been witnessed, due to kidney malfunction. This increases the demand for diagnosis of the initial stage of FSGS diseases during the treatment of kidney diseases. Thus, the burden of glomerulus-related disorders drives the global FSGS market during the forecast period. FSGS is the progressive scarring of the kidney, which is characterized by proteinuria. It is among the rare diseases, which affects kidney function by attacking and damaging the glomeruli. This disease is characterized by kidney defects by birth, obesity, obstructive sleep apnea, sickle cell anemia, viruses, such as HIV, among others.

To Request a Sample of our Report on Focal Segmental Glomerulosclerosis Market: https://www.omrglobal.com/request-sample/focal-segmental-glomerulosclerosis-market

Primary FSGS has become one of the most common causes of idiopathic glomerular disease in adults. The primary FSGS is usually idiopathic, which refers to the rise of disease without any known, definite or apparent reason. It has several prototypical characteristics and is the most common form in adolescents and young adults. The current therapy for the primary FSGS includes immunosuppressive agents, such as glucocorticoids and calcineurin inhibitors. Steroid therapy is among the most basic and standard treatment with oral prednisone. Some of the emerging companies having their potential drug candidates in the pipeline which include Chemocentryx, Reata, Pharmaceuticals, Retrophin Inc., and Vertex Pharmaceuticals. Since it is a rare disease, specialty clinical-stage companies are likely to get more funds that can leverage the strategic partnership opportunities. Moreover, the companies are directing their R&D efforts toward more targeted therapies as a solution to traditional drug and surgical treatments, which in turn, is expected to fuel the growth of the global focal segmental glomerulosclerosis market.

Market Coverage

• The market number available for - 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

Segment Covered-

• By Disease Type

• By Disease Management

• By Treatment

Regions covered-

· North America

· Europe

· Asia-Pacific

· Rest of the World

Competitive Landscape: Novartis International AG, Variant Pharmaceuticals, Inc., and AbbVie Inc., among others.

(Get 15% Discount on Buying this Report)

A full Report of Focal Segmental Glomerulosclerosis Market is Available @ https://www.omrglobal.com/industry-reports/focal-segmental-glomerulosclerosis-market

Global Focal Segmental Glomerulosclerosis Market Report by Segment

By Disease Type

• Primary FSGS

• Secondary FSGS

By Disease Management

Ø Diagnosis

· Kidney Biopsy

· Creatinine Test

· Other Diagnosis

Ø Treatment

· Drug Therapy

· Dialysis

· Kidney Transplant

Global Focal Segmental Glomerulosclerosis Market Report by Region

North America

· United States

· Canada

Europe

· UK

· Germany

· Spain

· France

· Italy

· Rest of Europe

Asia-Pacific

· India

· China

· Japan

· South Korea

· Rest of APAC

Rest of the World

· Latin America

· Middle East & Africa

Reasons to buy from us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.

2. More than 120 countries are for analysis.

3. Over 100+ paid data sources mined for investigation.

4. Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:

Company Name: Orion Market Research

Contact Person: Mr. Anurag Tiwari

Email: info@omrglobal.com

Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Focal Segmental Glomerulosclerosis Market Size, Share, Analysis, Industry Report and Forecast 2021-2027 here

News-ID: 2571763 • Views:

More Releases from Orion Market Research

AI-Enabled Imaging Modalities Market Rising Demand and Growth Forecast Through 2033
AI-Enabled Imaging Modalities Market Rising Demand and Growth Forecast Through 2 …
AI-enabled imaging modalities market was valued at approximately USD 1.36 billion, and it is projected to reach around USD 19.78 billion by 2033, reflecting a compound annual growth rate (CAGR) of about 34.67% from 2024 to 2033. AI-Enabled Imaging Modalities Market Overview The AI-enabled imaging modalities market is experiencing rapid growth, driven by advancements in artificial intelligence and machine learning technologies. These innovations are enhancing the capabilities of various imaging modalities, including
Tumor Tracking Systems Market Size Analysis, Competitive Insights, Leading Players and Growth Opportunities by 2033
Tumor Tracking Systems Market Size Analysis, Competitive Insights, Leading Playe …
Global tumor tracking systems market was valued at approximately USD 3.5 billion, and it is projected to reach around USD 6.6 billion by 2033, reflecting a compound annual growth rate (CAGR) of about 5% from 2024 to 2033. Tumor Tracking Systems Market Overview The tumor tracking systems market is experiencing steady growth, driven by the increasing incidence of cancer and advancements in imaging and tracking technologies. These systems improve the precision of
Tumor Tracking Systems Market Size Future Scope, Demands and Projected Industry Growths to 2033
Tumor Tracking Systems Market Size Future Scope, Demands and Projected Industry …
Tumor tracking systems market was valued at approximately USD 3.5 billion, and it is projected to reach around USD 6.6 billion by 2033, reflecting a compound annual growth rate (CAGR) of about 5% from 2024 to 2033. Tumor Tracking Systems Market Overview The tumor tracking systems market is experiencing steady growth, driven by the increasing prevalence of cancer and advancements in imaging technologies. These systems play a crucial role in enhancing the
SNP genotyping Market Size Analysis, Competitive Insights, Leading Players and Growth Opportunities by 2033
SNP genotyping Market Size Analysis, Competitive Insights, Leading Players and G …
SNP genotyping market was valued at approximately USD 31.66 billion, and it is projected to reach around USD 238.25 billion by 2034, reflecting a compound annual growth rate (CAGR) of about 20.1% from 2024 to 2034. SNP genotyping Market Overview The SNP genotyping market is experiencing significant growth, driven by advancements in genotyping technologies, an increase in the prevalence of genetic disorders, and the expansion of pharmacogenomics and precision medicine initiatives. This

All 5 Releases


More Releases for FSGS

Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Market New Product De …
As of 2024, the global market for treatments of Focal Segmental Glomerulosclerosis (FSGS) is valued at approximately $1.3 billion. With increasing incidences of kidney-related diseases and advancing therapeutic options, the market is projected to reach around $2.5 billion by 2034, representing a robust growth trajectory. The estimated Compound Annual Growth Rate (CAGR) for this period is approximately 7.5%. Exactitude Consultancy., Ltd. released a research report offers a comprehensive examination of the
Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine Market Size, Share, G …
The report presents detailed information regarding the prominent players and potential competitors in the Focal Nodular Glomerulosclerosis (FSGS) Treatment Medicine market. It includes comprehensive insights into their worldwide presence, economic performance, strategies, upcoming product releases, research and development initiatives, and a SWOT analysis. Additionally, the report analyses revenue share and contact details for each player. This comprehensive report aims to evaluate and forecast the market size for Fuel Monitoring Systems. It
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market - Transforming Kid …
Newark, New Castle, USA: The "Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors. Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market: https://www.growthplusreports.com/report/focal-segmental-glomerulosclerosis-fsgs-therapeutics-market/8837 This latest report
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market - Restoring Kidney …
Newark, New Castle, USA - new report, titled Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Focal Segmental Glomerulosclerosis (FSGS) Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Focal Segmental Glomerulosclerosis (FSGS) Therapeutics market.
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market Size [2023-2031] - …
Newark, New Castle, USA - The latest report from Growth Plus Reports analyzes the production, potential applications, demand, major manufacturers, and SWOT analysis of the global Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market. The Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market Report assists in determining the optimum distribution methods for certain products as well as possible markets for future product launches. The report also analyses the purchase and supply trends that influence the
Focal Segmental Glomerulosclerosis (FSGS) Market Insights Shared in Detailed Rep …
Focal Segmental Glomerulosclerosis (FSGS) Market:Overview The focal segmental glomerulosclerosis (FSGS) market is highly competitive due to presence of numerous large players and presence of local players. Some of the key participants in the global market for focal segmental glomerulosclerosis (FSGS) are Variant Pharmaceuticals, Inc., GlaxoSmithKline plc., Novartis AG, ChemoCentryx, Inc., and Retrophin, Inc. The global focal segmental glomerulosclerosis (FSGS) market will likely see continued changes in its contours with the successful